This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Amarin's Fish Oil Pill Faces Even More Exclusivity Risks

Generic drug companies don't market their products, but in this case, Amarin would be doing the marketing for them.

If you think through this scenario, it helps explain why Amarin was never acquired early on, and why the company was forced to launch Vascepa on its own. Big Pharma makes many mistakes, but one area where big drug companies excel is figuring out intellectual property and marketing exclusivity issues. [Crucial for determining the real value of a pharmaceutical asset.]

My investor source believes Big Pharma determined early on that Vascepa's copycat active moiety and overlapping initial approval (relative to Lovaza) make it too easy for a generic copy to undercut the market. Amarin's still has Vascepa patents in place for protection, of course, but generic drug makers could figure out a way to work around the patents or get them invalidated by the courts.

For Big Pharma, these risks are too high, which is why Amarin's troubles aren't going away, even if Vascepa wins an expanded label later this year.

One more thing: Total Vascepa prescriptions for the week ended April 12, totaled 1,870, up 15% from the week of April 5, according to IMS Health. Amarin's slow Vascepa launch continues.

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.
2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AMRN $1.28 -3.00%
GSK $39.15 0.05%
AAPL $93.65 -0.66%
FB $101.93 0.92%
GOOG $681.92 -0.32%


Chart of I:DJI
DOW 15,660.18 -254.56 -1.60%
S&P 500 1,829.08 -22.78 -1.23%
NASDAQ 4,266.8370 -16.7550 -0.39%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs